Clinical Trial Update: Combination Daclizumab/Denileukin Diftitox to Treat Uveitis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a combination of daclizumab and denileukin diftitox for non-infectious intermediate and posterior uveitis has completed, sponsored by t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-infectious Intermediate Uveitis
• Non-infectious Posterior Uveitis

Drugs mentioned

• Daclizumab (daclizumab)
• Denileukin diftitox (denileukin diftitox)

Snippet

Sponsor: National Eye Institute (NEI) | Conditions: Non-infectious Intermediate and Posterior Uveitis | Phase 2 | Status: COMPLETED